We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




DiaSorin’s Luminex Subsidiary to Spin Off Flow Cytometry Business to Cell Analysis Leader

By LabMedica International staff writers
Posted on 15 Feb 2023
Print article
Image: With the acquisition, an existing installed base of over 7,000 instruments will be under the Cytek umbrella (Photo courtesy of Luminex)
Image: With the acquisition, an existing installed base of over 7,000 instruments will be under the Cytek umbrella (Photo courtesy of Luminex)

DiaSorin S.p.A. (‎Saluggia‎, Italy) and Cytek Biosciences, Inc. (Fremont, CA, USA) have announced that Luminex Corporation (Austin, TX, USA), a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit.

The FCI business unit, acquired by Luminex in October 2018, is based on both conventional flow cytometry and image-based flow cytometry instrumentation, which provide insights into all facets of cellular phenotypes and morphology. The FCI business unit includes dedicated commercial, operations, R&D, and supporting personnel. Following the acquisition, the Cytek umbrella will have an existing installed base of over 7,000 instruments, expanding its global commercial footprint.

With the addition of first-to-market Amnis imaging flow cytometers to its range of cell analysis solutions, Cytek can offer tools to researchers and scientists that combine high-resolution cell images with the speed, sensitivity and phenotyping abilities of flow cytometry. The addition of Guava flow cytometers will expand Cytek’s core instrument offerings, adding cost-effective, entry-level and personal instrument options to broaden the market and research areas serviced by the company.

“We are currently working on several projects that will allow DiaSorin to further growth and strengthen our positioning as a specialty player over the next years,” said Angelo Rago, president of Luminex. “To do so, we need to be extremely focused on the core for our future and, therefore, we decided to sell the Flow Cytometry & Imaging business unit to a dedicated, leading player in the space. We are convinced that Cytek will be able to grow it with success in the future.”

“The talent and technology that come along with this acquisition will bolster our offerings to address the current market and further our mission to provide a complete cell analysis solution to our customers,” added Wenbin Jiang, CEO of Cytek Biosciences. “We look forward to welcoming Luminex’s flow cytometry team into our own and working together to serve our customers and to move cellular research forward.”

Related Links:
DiaSorin S.p.A
Luminex Corporation
Cytek Biosciences, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Ultrasound-based duplex sonography combined with a new genetic testing procedure can identify clonal haematopoiesis (Photo courtesy of 123RF)

New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk

A key interest area in cardiovascular research today is the impact of clonal hematopoiesis on cardiovascular diseases. Clonal hematopoiesis results from mutations in hematopoietic stem cells and may lead... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.